Core Insights - Cytek Biosciences reported a total revenue of $52.3 million for Q3 2025, reflecting a 2% increase compared to Q3 2024, driven by growth in the US, APAC, and other regions, despite a decline in EMEA [4][10] - The company experienced a GAAP gross profit of $27.6 million, a 5% decrease from the previous year, with a gross profit margin of 53% compared to 56% in Q3 2024 [5][10] - Operating expenses rose to $36.7 million, a 10% increase year-over-year, primarily due to a significant rise in general and administrative expenses [6][8] - The company reported a loss from operations of $9.2 million, compared to a loss of $4.2 million in Q3 2024, and a net loss of $5.5 million compared to a net income of $0.9 million in the same period last year [9][10] - Cytek's total recurring revenue grew by 19% year-over-year, indicating strong performance in service and reagent revenues [10] - The company reaffirmed its 2025 revenue guidance, expecting total revenue to be in the range of $196 million to $205 million, representing a growth of -2% to +2% over 2024 [12] Financial Performance - Total revenue for Q3 2025 was $52.3 million, up from $51.5 million in Q3 2024 [4][10] - GAAP gross profit was $27.6 million, down from $29.0 million in Q3 2024, with a gross profit margin of 53% [5][10] - Operating expenses were $36.7 million, with R&D expenses at $9.0 million (down 9%) and sales and marketing expenses at $11.7 million (down 6%) [6][7] - The net loss for Q3 2025 was $5.5 million, compared to a net income of $0.9 million in Q3 2024 [9][10] Strategic Developments - The installed base of Cytek instruments expanded to 3,456, with 161 new units added in Q3 2025 [10] - The company expanded its European headquarters in Amsterdam, increasing its footprint by over 40% [10] - Cytek's revenue from biotechnology, pharmaceutical, and clinical research organization customers grew by 14% year-over-year [10]

Core Insights - Cytek Biosciences, Inc. will report its financial results for Q3 2025 on November 5, 2025, after market close, followed by a conference call to discuss the results and outlook [1] Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [2] - The company's product offerings include FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Orion™, along with various reagents and software, providing a comprehensive suite of solutions for customers [2] - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [2] Product Usage - Cytek's products are intended for research use only, with specific exceptions for clinical use in China and the European Union for certain systems and reagents [3] Information Distribution - The company utilizes multiple channels, including its website, LinkedIn, and X account, to disseminate material information and comply with disclosure obligations under Regulation FD [4]

Core Viewpoint - Cytek Biosciences, Inc. will report its financial results for Q2 2025 on August 6, 2025, followed by a conference call to discuss the results and business outlook [1]. Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [2]. - The company's product offerings include FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Orion™, along with various reagents, software, and services [2]. - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [2]. Product Usage - Cytek's products are intended for research use only, with specific exceptions for clinical use in China and the European Union for certain systems and reagents [3]. Information Distribution - The company utilizes its website, LinkedIn, and X (formerly Twitter) for distributing material information and compliance with disclosure obligations under Regulation FD [4].